BRPI0810951A2 - Proteína l1 hpv6, polinucleotídeo, vetor, célula, composição, partícula semelhante ao vírus (vlp) hpv6, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções porhpv, uso da proteína, método para prevenção de condiloma acuminado ou infecções por hpv, método pra obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv - Google Patents

Proteína l1 hpv6, polinucleotídeo, vetor, célula, composição, partícula semelhante ao vírus (vlp) hpv6, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções porhpv, uso da proteína, método para prevenção de condiloma acuminado ou infecções por hpv, método pra obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv

Info

Publication number: BRPI0810951A2
Authority: BR; Brazil
Prior art keywords: protein; hpv6; prevention; condyloma; acuminate
Prior art date: 2007-05-29

Application number

BRPI0810951-6A

Other languages

English (en)

Inventor

Shaowei Li

Huirong Pan

Bo Liu

Jun Zhang

Ji Miao

Ningshao Xia

Original Assignee

Univ Xiamen

Beijing Wantai Biological Pharmacy Entpr Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-29

Filing date

2008-05-29

Publication date

2015-07-21

2008-05-29 Application filed by Univ Xiamen, Beijing Wantai Biological Pharmacy Entpr Co Ltd filed Critical Univ Xiamen

2015-07-21 Publication of BRPI0810951A2 publication Critical patent/BRPI0810951A2/pt

2020-10-06 Publication of BRPI0810951B1 publication Critical patent/BRPI0810951B1/pt

2021-05-25 Publication of BRPI0810951B8 publication Critical patent/BRPI0810951B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2796/00—Viruses not covered by groups C12N2710/00 - C12N2795/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

BRPI0810951A 2007-05-29 2008-05-29 proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv BRPI0810951B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CN200710105764.7		2007-05-29
CN200710105764		2007-05-29
PCT/CN2008/001050 WO2008145021A1 (fr)	2007-05-29	2008-05-29	Protéine l1 tronquée du papillomavirus humain de type 6

Publications (3)

Publication Number	Publication Date
BRPI0810951A2 true BRPI0810951A2 (pt)	2015-07-21
BRPI0810951B1 BRPI0810951B1 (pt)	2020-10-06
BRPI0810951B8 BRPI0810951B8 (pt)	2021-05-25

Family

ID=40074567

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0810951A BRPI0810951B8 (pt)	2007-05-29	2008-05-29	proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv

Country Status (6)

Country	Link
US (2)	US8748127B2 (pt)
EP (1)	EP2154149B1 (pt)
CN (1)	CN101343315B (pt)
BR (1)	BRPI0810951B8 (pt)
DK (1)	DK2154149T3 (pt)
WO (1)	WO2008145021A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102268076B (zh) *	2010-07-02	2017-04-26	厦门大学	截短的人乳头瘤病毒52型l1蛋白
CN102229660B (zh) *	2011-05-25	2015-04-22	厦门大学	截短的人乳头瘤病毒33型l1蛋白
CN105039358B (zh) *	2013-12-03	2020-02-28	北京康乐卫士生物技术股份有限公司	58型重组人乳头瘤病毒病毒样颗粒及其制备方法
US20180289792A1 (en) *	2015-10-22	2018-10-11	ModernaTX. Inc.	Sexually transmitted disease vaccines
CN106831960B (zh) *	2015-12-04	2019-11-05	厦门大学	一种人乳头瘤病毒6型l1蛋白的突变体
WO2017092711A1 (zh)	2015-12-04	2017-06-08	厦门大学	一种人乳头瘤病毒11型l1蛋白的突变体
US11771754B2 (en) *	2018-06-04	2023-10-03	Xiamen University	Mutant of L1 protein of human papillomavirus type 18
US20220290262A1 (en) *	2019-01-25	2022-09-15	Psomagen Inc.	Antibody-dna conjugates and hpv detection and treatment
AU2020317321B2 (en)	2019-07-19	2023-07-27	Sinocelltech Ltd.	Polyvalent immunogenicity composition for human papillomavirus
CN114539364B (zh) *	2020-11-26	2023-10-20	中国医学科学院基础医学研究所	一种c端改造的人乳头瘤病毒6型l1蛋白及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3110561A1 (de) *	1981-03-18	1982-11-04	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen	Chemorekrutine der leukozyten und des entszuendungsgewebes: eine neue klasse natuerlicher leukopoetine zurselektiven chemorekrutierung von leukozyten aus dem knochenmark in den blutstrom (leukozytose- und linskverschiebungsreaktion)
FR2672895B1 (fr) *	1991-02-15	1995-05-12	Transgene Sa	Procede de purification d'une proteine fortement glycosylee.
DE05075369T1 (de)	1993-03-09	2006-11-16	The University Of Rochester	Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen
AUPM566794A0 (en) *	1994-05-17	1994-06-09	University Of Queensland, The	Process and product
IL113817A (en) *	1994-06-30	2001-03-19	Merck & Co Inc	Polynucleotide vaccne for papillomavirus
DE122007000093I1 (de) *	1994-10-07	2008-03-27	Univ Loyola Chicago	Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
US7351533B2 (en) *	1997-09-05	2008-04-01	Medimmune, Inc.	In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) *	1997-10-06	2001-05-08	Loyola University Of Chicago	Papilloma virus capsomere formulations and method of use
US7182947B2 (en)	1998-02-20	2007-02-27	Medigene Ag	Papillomavirus truncated L1 protein and fusion protein constructs
US20020193565A1 (en) *	1998-03-27	2002-12-19	Stanley Margaret Anne	Antigen preparation and use
EA200100236A1 (ru) *	1998-08-14	2001-08-27	Мерк Энд Ко., Инк.	Способ очистки вирусных частиц, подобных вирусу папилломы человека
US6551597B1 (en)	1999-03-18	2003-04-22	President & Fellows Of Harvard College	Vaccine compositions for human papillomavirus
GB0206359D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
GB0206360D0 (en) *	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
CN1293093C (zh) *	2002-08-30	2007-01-03	马润林	乳头瘤病毒衣壳蛋白的原核制备和应用
MY139500A (en) *	2003-11-12	2009-10-30	Merck Sharp & Dohme	Optimized expression of hpv 58 l1 in yeast
CN101153280B (zh)	2006-09-29	2015-08-19	厦门大学	从原核生物中纯化人乳头瘤病毒晚期蛋白l1的方法
GB0624227D0 (en) *	2006-12-05	2007-01-10	Common Services Agency	Protein purification
AU2008226974B2 (en) *	2007-03-09	2013-08-15	Merck Sharp & Dohme Llc	Papillomavirus vaccine compositions
BRPI0815818A2 (pt) *	2007-04-29	2016-08-02	Beijing Wantai Biological Pharmacy Entpr Co Ltd	proteína l1 truncada do papiloma vírus humano tipo 18
DK2154147T3 (en) *	2007-04-29	2015-12-07	Beijing Wantai Biological Pharmacy Entpr Co Ltd	Truncated L1 protein of human papillomavirus 16
EP2907821B1 (en) *	2007-05-29	2016-12-28	Xiamen University	Method for producing a N-terminaly truncated L1 protein of human papillomavirus (HPV)

2008
- 2008-05-29 WO PCT/CN2008/001050 patent/WO2008145021A1/zh not_active Ceased
- 2008-05-29 BR BRPI0810951A patent/BRPI0810951B8/pt active IP Right Grant
- 2008-05-29 DK DK08757381.2T patent/DK2154149T3/da active
- 2008-05-29 EP EP08757381.2A patent/EP2154149B1/en active Active
- 2008-05-29 US US12/601,972 patent/US8748127B2/en active Active
- 2008-05-29 CN CN2008101113904A patent/CN101343315B/zh active Active
2014
- 2014-04-08 US US14/248,063 patent/US9745351B2/en active Active

Also Published As

Publication number	Publication date
US9745351B2 (en)	2017-08-29
BRPI0810951B8 (pt)	2021-05-25
CN101343315B (zh)	2012-06-13
WO2008145021A1 (fr)	2008-12-04
EP2154149A1 (en)	2010-02-17
US20140288283A1 (en)	2014-09-25
US8748127B2 (en)	2014-06-10
BRPI0810951B1 (pt)	2020-10-06
HK1124343A1 (en)	2009-07-10
EP2154149B1 (en)	2019-07-10
CN101343315A (zh)	2009-01-14
EP2154149A4 (en)	2011-04-06
US20100255021A1 (en)	2010-10-07
DK2154149T3 (da)	2019-10-14

Publication	Publication Date	Title
BRPI0810951A2 (pt)	2015-07-21	Proteína l1 hpv6, polinucleotídeo, vetor, célula, composição, partícula semelhante ao vírus (vlp) hpv6, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções porhpv, uso da proteína, método para prevenção de condiloma acuminado ou infecções por hpv, método pra obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
BRPI0810959A2 (pt)	2015-07-21	"proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícular semelhante ao vírus (vlp) hp11, método para produzir uma proteína l1 do hpv,vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína método para prevenção de condiloma acuminado ou infecções por hpv e método para prevenção de condiloma acuminado ou infecções por hpv.
IL203869A (en)	2016-05-31	Method of Preparing a Containing a Virus or Antigen Antigen, Various Aspects Related to This Method, Uses of a Method and Vaccination of a Split Virus Prepared by This Method
EP2416798A4 (en)	2013-01-09	PAPILLOMAVIRUS LIKE PARTICLES (VLP) AS WIDE BAND VACCINES AGAINST HUMAN PAPILLOMA VIRUS (HPV)
BRPI0915896A2 (pt)	2019-09-24	ácido nucleico, método para produzir partículas similares ao vírus influenza (vlps) em uma planta, as ditas partículas similares ao vírus (vlp), uso das mesmas e composição
WO2007130330A3 (en)	2008-03-06	Polyvalent influenza virus-like particle (vlp) compositions
WO2007130327A3 (en)	2008-09-12	Influenza virus-like particle (vlp) compositions
EP2536428A4 (en)	2014-04-09	UNIVERSAL INFLUENZA VACCINES WITH VIRUSIC PARTICLES
WO2017040387A3 (en)	2017-04-20	Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
WO2010001409A3 (en)	2010-05-27	Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2014145932A3 (en)	2015-11-05	Specific multivalent virus-like particle vaccines and uses thereof
EP2119451A4 (en)	2012-05-16	LYOPHILIZED PREPARATION COMPRISING THE INFLUENZA VACCINE AND PREPARATION METHOD THEREOF
WO2017192418A8 (en)	2019-05-23	Therapeutic hpv vaccine combinations
EP3856240A4 (en)	2022-09-28	COMPOSITIONS AND METHODS OF MANUFACTURE AND USE OF VIRUS-LIKE PARTICLES (VLPS)
ZA201004337B (en)	2012-12-27	Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing the same
HUS1500059I1 (hu)	2017-10-30	A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
BRPI1007584A2 (pt)	2016-12-06	vacina de sarampo-malária combinada, vetor de vírus de vacina de sarampo, hospedeiro e composição de vacina de sarampo-malária combinada
WO2010040572A3 (en)	2010-08-19	Antibodies against h5n1 influenza viruses
HK1220736A1 (zh)	2017-05-12	尿液中的hpv檢測
WO2014008475A3 (en)	2014-04-10	Compositions and methods related to viral vaccines
BRPI0819889A2 (pt)	2015-06-16	Vetor viral, composição, vacina, composição de vacina, kit, processos para a preparação de um vetor viral e para a preparação de uma composição, uso de um vetor viral, e, método de tratamento
WO2010033619A3 (en)	2010-06-24	Systems, methods, and compositions for detection of human papilloma virus in biological samples
MX2014000522A (es)	2014-05-30	Composicion y metodo para tratar virus del papiloma humano (vph).
HK1125388A (en)	2009-08-07	Hpv antigens, vaccine compositions, and related methods
HK1196785A (en)	2014-12-24	Composition and method for treating hpv

Legal Events

Date	Code	Title	Description
2018-01-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-08-27	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-01-14	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-02-11	B25A	Requested transfer of rights approved	Owner name: XIAMEN UNIVERSITY (CN) ; XIAMEN INNOVAX BIOTECH CO., LTD. (CN)
2020-05-12	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-10-06	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF